Clinical Trial Update: A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults [Phase 2]

View source ↗

Summary

Phase 2 trial of GSK3640254 plus dolutegravir in treatment-naive HIV-1 adults was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Dolutegravir (dolutegravir)
• GSK3640254

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 2 | Status: TERMINATED | Results posted: 2023-12-14